Drug Trial Radar · NCT05768997
High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia
Last checked: Nov 20, 2026Latest source record: Mar 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
312
Planned (sponsor's estimate)
Start
Mar 1, 2023
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Hallym University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, prospective, randomized phase 3 clinical study comparing the efficacy and safety of the combination treatment of ESA and high-dose IV iron (darbepoietin alfa + ferric derisomaltose/iron isomaltoside) with ESA monotherapy (darbepoietin alfa alone) in CIA patients with functional iron deficiency.
Conditions
- Anemia
Interventions
Ferric Derisomaltose InjectionDrug
Ferric derisomaltose/iron isomaltoside (as iron) (0 weeks): 20mg/kg, diluted in 250ml of 0.9% physiological saline and injected intravenously over 30-60 minutes
Darbepoetin Alfa InjectionDrug
Darbepoietin alfa (0 weeks, 3 weeks, 6 weeks, 9 weeks): 6.75㎍/kg, subcutaneous or intravenous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Hb changeTime frame: from baseline to 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hallym University Medical Center
Anyang-si, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.